We are glad to announce U.S. FDA IND acceptance to conduct a phase 1/2 clinical trial of NT-219 for treatment of recurrent or metastatic solid tumors and head and neck cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.